BACKGROUND: This study evaluated long-term outcomes in patients with pulmonary arterial hypertension (PAH) undergoing treatment with ambrisentan monotherapy, a selective oral endothelin-1 receptor antagonist. METHODS AND RESULTS: Patients who participated in the Ambrisentan in Pulmonary Arterial Hypertension: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy Study (ARIES-1) clinical trial and extension phase at our institution were included. Cardiac catheterization, 6-minute walk distance (6MWD), and cardiac magnetic resonance (MRI) data were retrospectively reviewed. Twelve patients with PAH (11 idiopathic, 1 fenfluramine) had follow-up from 3 to 5.5 years from the initiation of ARIES-1. Patients received ambrisentan therapy throughout the study period and were on ambrisentan monotherapy for the first 2 years. At year 1, improvements in median mean pulmonary arterial pressure (PA), cardiac output, and pulmonary vascular resistance (PVR) were seen (P = .02, P = .03, P < .01), and the improvement in PVR persisted at 2 years. 6MWD also improved significantly between baseline (350 m) and 1 and 2 years (397 m, P < .01 and 393 m, P = .01). Cardiac MRI results were more varied, with an increase in RV ejection fraction from 29% at baseline to 46% at 2 years (P = .02), but other MRI variables did not improve. CONCLUSIONS:Ambrisentan monotherapy led to improvements in catheterization, 6MWD, and RV ejection fraction, and shows promise as a long-term treatment for pulmonary arterial hypertension. Copyright 2010 Elsevier Inc. All rights reserved.
RCT Entities:
BACKGROUND: This study evaluated long-term outcomes in patients with pulmonary arterial hypertension (PAH) undergoing treatment with ambrisentan monotherapy, a selective oral endothelin-1 receptor antagonist. METHODS AND RESULTS:Patients who participated in the Ambrisentan in Pulmonary Arterial Hypertension: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy Study (ARIES-1) clinical trial and extension phase at our institution were included. Cardiac catheterization, 6-minute walk distance (6MWD), and cardiac magnetic resonance (MRI) data were retrospectively reviewed. Twelve patients with PAH (11 idiopathic, 1 fenfluramine) had follow-up from 3 to 5.5 years from the initiation of ARIES-1. Patients received ambrisentan therapy throughout the study period and were on ambrisentan monotherapy for the first 2 years. At year 1, improvements in median mean pulmonary arterial pressure (PA), cardiac output, and pulmonary vascular resistance (PVR) were seen (P = .02, P = .03, P < .01), and the improvement in PVR persisted at 2 years. 6MWD also improved significantly between baseline (350 m) and 1 and 2 years (397 m, P < .01 and 393 m, P = .01). Cardiac MRI results were more varied, with an increase in RV ejection fraction from 29% at baseline to 46% at 2 years (P = .02), but other MRI variables did not improve. CONCLUSIONS:Ambrisentan monotherapy led to improvements in catheterization, 6MWD, and RV ejection fraction, and shows promise as a long-term treatment for pulmonary arterial hypertension. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Nazzareno Galiè; Alan L Hinderliter; Adam Torbicki; Thierry Fourme; Gerald Simonneau; Tomas Pulido; Nilda Espinola-Zavaleta; Guido Rocchi; Alessandra Manes; Robert Frantz; Marcin Kurzyna; Sherif F Nagueh; Robyn Barst; Richard Channick; Karl Dujardin; Andrew Kronenberg; Isabelle Leconte; Maurizio Rainisio; Lewis Rubin Journal: J Am Coll Cardiol Date: 2003-04-16 Impact factor: 24.094
Authors: Olivier Sitbon; David B Badesch; Richard N Channick; Adaani Frost; Ivan M Robbins; Gérald Simonneau; Victor F Tapson; Lewis J Rubin Journal: Chest Date: 2003-07 Impact factor: 9.410
Authors: Roald J Roeleveld; Anton Vonk-Noordegraaf; J Tim Marcus; Jean G F Bronzwaer; Koen M J Marques; Pieter E Postmus; Anco Boonstra Journal: Chest Date: 2004-02 Impact factor: 9.410
Authors: Frank Grothues; James C Moon; Nicholas G Bellenger; Gillian S Smith; Helmut U Klein; Dudley J Pennell Journal: Am Heart J Date: 2004-02 Impact factor: 4.749
Authors: G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis Journal: Ann Intern Med Date: 1991-09-01 Impact factor: 25.391
Authors: Nazzareno Galiè; Horst Olschewski; Ronald J Oudiz; Fernando Torres; Adaani Frost; Hossein A Ghofrani; David B Badesch; Michael D McGoon; Vallerie V McLaughlin; Ellen B Roecker; Michael J Gerber; Christopher Dufton; Brian L Wiens; Lewis J Rubin Journal: Circulation Date: 2008-05-27 Impact factor: 29.690
Authors: Edward A Pankey; Matthew Epps; Bobby D Nossaman; Albert L Hyman; Philip J Kadowitz Journal: J Clin Rheumatol Musculoskelet Med Date: 2010-12-01
Authors: Chunhua Jin; Yejoo Jeon; Daniel T Kleven; Jennifer S Pollock; John J White; David M Pollock Journal: J Pharmacol Exp Ther Date: 2014-09-04 Impact factor: 4.030